{"context":{"query":">>mesh>>pharmgkb_clinical","source_dataset":"mesh","target_dataset":"pharmgkb_clinical"},"stats":{"queried":1,"total":11,"mapped":1},"pagination":{"has_next":false},"schema":"id|variant|gene|type|level_of_evidence|chemicals|phenotypes","mappings":[{"input":"D009101","source":"D009101|Multiple Myeloma","targets":["RS1045642_ABCB1_2|rs1045642|ABCB1|Efficacy|3|dexamethasone;doxorubicin;vincristine|Multiple Myeloma","RS1051685_XRCC5_1|rs1051685|XRCC5|Efficacy|3|thalidomide|Multiple Myeloma","RS1934951_CYP2C8_1|rs1934951|CYP2C8|Toxicity|4|Bisphosphonates;pamidronate;zoledronate|Multiple Myeloma;Osteonecrosis","RS2032582_ABCB1_1|rs2032582|ABCB1|Efficacy|3|dexamethasone;doxorubicin;vincristine|Multiple Myeloma","RS2229109_ABCB1_5|rs2229109|ABCB1|Efficacy|3|dexamethasone;lenalidomide|Multiple Myeloma;Progression-free survival","RS308395_FGF2_1|rs308395|FGF2|Efficacy|3|lenalidomide;thalidomide|Multiple Myeloma","RS4135385_CTNNB1_1|rs4135385|CTNNB1|Efficacy,Toxicity|3|cyclophosphamide;dexamethasone;lenalidomide;thalidomide|Multiple Myeloma","RS4240803_SLC7A5_1|rs4240803|SLC7A5|Toxicity|3|melphalan|Multiple Myeloma","RS4533622_CTNNB1_1|rs4533622|CTNNB1|Efficacy,Toxicity|3|lenalidomide;thalidomide|Multiple Myeloma","RS4630_GSTT1_1|rs4630|GSTT1|Toxicity|3|thalidomide|Multiple Myeloma","RS735482_ERCC1_1|rs735482|ERCC1|Efficacy|3|thalidomide|Multiple Myeloma"]}]}